In vitro antibacterial activity of eravacycline against multidrug-resistant Acinetobacter baumannii isolates

Ataman M., Mataraci-Kara E., Ozbek-Celik B.

JOURNAL OF RESEARCH IN PHARMACY, cilt.25, sa.5, ss.549-553, 2021 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 5
  • Basım Tarihi: 2021
  • Doi Numarası: 10.29228/jrp.45
  • Dergi Adı: JOURNAL OF RESEARCH IN PHARMACY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.549-553
  • Anahtar Kelimeler: Non-fermentative, tetracycline, antibacterial agent, resistant bacteria, MIC, ENTEROBACTERIACEAE, COLISTIN
  • İstanbul Üniversitesi Adresli: Evet

Özet

The antibacterial effectiveness of eravacycline was compared with various antibiotics used in Acinetobacter therapy against multidrug-resistant (MDR) Acinetobacter baumannii strains. Antibacterial susceptibility studiea was achieved by the broth microdilution method against 52 non-duplicate, A. baumanniii strains to eravacycline, tobramycin, levofloxacin, cefepime, meropenem, and colistin. Eravacycline presented greater action than the comparators of the other group, cefepime, colistin, levofloxacin, and tobramycin. While the MIC50/90 values of eravacycline were 8/16 mg/ L and those for tobramycin, levofloxacin, cefepime, meropenem, and colistin were found 256/>256, 64/ >256, 256/ >256, 128/>256, and 0.5/256 mg/L, respectively. As a result, the present study showed that eravacycline was a potent effective antibiotic against MDR A. baumannii. Eravacycline could be an effective new alternative for use in particular, for the treatment of this problematic organism.